Mark Millich, 26 years old and insecure about his thinning hair, was curious about the ads he saw promising to reverse his ...

BofA analyst Allen Lutz notes that the Food and Drug Administration yesterday provided updated enforcement timelines for semaglutide and ...

The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN F ...

Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...

Citigroup reiterated their sell rating on shares of Hims & Hers Health (NYSE:HIMS – Free Report) in a research report report published on Thursday,Benzinga reports. They currently have a $27.00 price ...

Bank of America restated their underperform rating on shares of Hims & Hers Health (NYSE:HIMS – Free Report) in a research note published on Thursday morning,Benzinga reports. The brokerage currently ...

That’s why, as a 2016 Vox investigation found, there are many reports of vitamins and supplements containing ingredients that ...

Doctor, doctor, give me the news, Hims & Hers Health (HIMS) has got bad case of the stock market blues. The San Francisco ...

Hims & Hers (HIMS) stock falls 8% as court denies injunction on FDA ruling for Eli Lilly's (LLY) Zepbound shortage. Read more ...

Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth ...

Hims & Hers reported its Q4 earnings this week. The company is growing quickly but faces a potential legal threat to its ...

Would you like to be notified of the latest news and updates on the stock market?